When ResMed was formed in 1989, our primary purpose was to commercialize a device for treating obstructive sleep apnea (OSA), a major subset of sleep-disordered breathing (SDB).
In 1981, Professor Colin Sullivan and colleagues at the University of Sydney developed the first continuous positive airway pressure (CPAP) device, the first successful, noninvasive treatment for obstructive sleep apnea (OSA). In 1989, ResMed was founded to commercialize this device. Over the past 25 years, awareness about the dangers of untreated OSA has increased, and ResMed has introduced lighter, quieter and more comfortable equipment to help those with sleep apnea (and their bed partners) sleep and live better. We now help patients in more than 100 countries through ResMed offices and a vast network of equipment suppliers.
Since 1989, we have maintained our focus on SDB, while also expanding into the fields of respiratory medicine and cardiology. We help make quality care accessible for those with diseases such as chronic obstructive pulmonary disease (COPD) and motor neuron disease.
We have long recognized that more than 150 million Americans have problems sleeping at night and that, as specialists in sleep, we could use our deep knowledge to help not only track your sleep but also analyze and improve it. We’ve spent more than 10 years developing the S+ - analyzing more than 2 million nights of sleep to develop the very best solution available.
Most important, we wanted to develop a solution that was easy to use and accurate. So we tested S+ rigorously in 10 published clinical studies.
See the list of studies based on the technology that goes into S+ by ResMed:
Note: S+ is not a medical device. If you are seeking information on how to treat a sleep disorder, you should talk to your healthcare provider.